LLY
10-Q
Eli Lilly Q3 revenue surges 54% to $17.6B on Mounjaro/Zepbound strength; orforglipron succeeds
LLY · Filed October 30, 2025 · Period ending September 30, 2025 · ~2 min read
5 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade LLY commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
View original filing on SEC.gov
Generated by AI · May 14, 2026 7:35 PM